Literature DB >> 14748850

Inhibition of voltage-sensitive sodium channels by the cannabinoid 1 receptor antagonist AM 251 in mammalian brain.

Chengyong Liao1, Jian Zheng, Laurence S David, Russell A Nicholson.   

Abstract

The cannabinoid 1 receptor antagonist AM 251 is known to block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 receptors in brain. We examined the ability of AM 251 to inhibit sodium channel-dependent functions and the binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels in mouse brain synaptic preparations. Depolarization of synaptoneurosomes by the sodium channel site 2-specific neurotoxin veratridine, which is abolished by tetrodotoxin, was found to be inhibited in a concentration-dependent fashion by AM 251 (IC50=8.9 microM). Veratridine-dependent (tetrodotoxin suppressible) release, of L-glutamic acid and GABA from synaptosomes was also reduced by AM 251 [IC50s=8.5 microM (L-glutamic acid), 9.2 microM (GABA)]. The binding of the radioligand [3H]batrachotoxinin A 20-alpha-benzoate to site 2 on sodium channels was displaced by AM 251 (IC50=11.2 microM). Scatchard analysis of binding showed that at its IC50, AM 251 increased (by 2.3 times) the KD of radioligand without altering Bmax, suggesting a competitive mechanism of inhibition by AM 251. Kinetic experiments indicated that AM 251 inhibits equilibrium binding by allosterically accelerating the dissociation of the [3H]-batrachotoxinin A 20-alpha-benzoate:sodium channel complex. Our data suggest that micromolar concentrations of AM 251 are capable of reducing neuronal excitability and inhibiting release of excitatory and inhibitory transmitters through blockade of voltage-sensitive sodium channels in brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748850     DOI: 10.1111/j.1742-7843.2004.pto940204.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  6 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

3.  Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.

Authors:  Attila Köfalvi; Ricardo J Rodrigues; Catherine Ledent; Ken Mackie; E Sylvester Vizi; Rodrigo A Cunha; Beáta Sperlágh
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

4.  Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain.

Authors:  Gabriele Cenni; Patrizio Blandina; Ken Mackie; Daniele Nosi; Lucia Formigli; Patrizia Giannoni; Chiara Ballini; Laura Della Corte; Pier Francesco Mannaioni; M Beatrice Passani
Journal:  Eur J Neurosci       Date:  2006-09       Impact factor: 3.386

Review 5.  Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

6.  Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices.

Authors:  Aitziber Mendiguren; Joseba Pineda
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.